CTLA-4 Antisense Oligonucleotide Contributes to Enhanced Immunogenicity of an Adjuvanted Recombinant <i>Sporothrix</i> spp. Enolase Antigen.

Vaccines (Basel) · 2026 · PMC13119646 · PMID 42042810

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Although IL-2 levels showed an upward trend, the increase did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.

CTLA-4 Antisense Oligonucleotide Contributes to Enhanced Immunogenicity of an Adjuvanted Recombinant &lt;i&gt;Sporothrix&lt;/i&gt; spp. Enolase Antigen.

The sentences

CTLA-4 Antisense Oligonucleotide Contributes to Enhanced Immunogenicity of an Adjuvanted Recombinant <i>Sporothrix</i> spp. Enolase Antigen.